185 related articles for article (PubMed ID: 17601493)
21. Involvement of metabotropic glutamate receptor 5 in brain reward deficits associated with cocaine and nicotine withdrawal and somatic signs of nicotine withdrawal.
Stoker AK; Olivier B; Markou A
Psychopharmacology (Berl); 2012 May; 221(2):317-27. PubMed ID: 22147259
[TBL] [Abstract][Full Text] [Related]
22. DOI-induced deficits in prepulse inhibition in Wistar rats are reversed by mGlu2/3 receptor stimulation.
Wischhof L; Aho HE; Koch M
Pharmacol Biochem Behav; 2012 Jul; 102(1):6-12. PubMed ID: 22469865
[TBL] [Abstract][Full Text] [Related]
23. Bupropion enhances brain reward function and reverses the affective and somatic aspects of nicotine withdrawal in the rat.
Cryan JF; Bruijnzeel AW; Skjei KL; Markou A
Psychopharmacology (Berl); 2003 Jul; 168(3):347-58. PubMed ID: 12698231
[TBL] [Abstract][Full Text] [Related]
24. The group II metabotropic glutamate receptor agonist LY379268 reduces toluene-induced enhancement of brain-stimulation reward and behavioral disturbances.
Chan MH; Tsai YL; Lee MY; Stoker AK; Markou A; Chen HH
Psychopharmacology (Berl); 2015 Sep; 232(17):3259-68. PubMed ID: 26044619
[TBL] [Abstract][Full Text] [Related]
25. Decreased brain reward function during nicotine withdrawal in C57BL6 mice: evidence from intracranial self-stimulation (ICSS) studies.
Johnson PM; Hollander JA; Kenny PJ
Pharmacol Biochem Behav; 2008 Sep; 90(3):409-15. PubMed ID: 18466962
[TBL] [Abstract][Full Text] [Related]
26. Pre-treatment with the mGlu2/3 receptor agonist LY379268 attenuates DOI-induced impulsive responding and regional c-Fos protein expression.
Wischhof L; Koch M
Psychopharmacology (Berl); 2012 Jan; 219(2):387-400. PubMed ID: 21863235
[TBL] [Abstract][Full Text] [Related]
27. Blockade of CRF1 receptors in the central nucleus of the amygdala attenuates the dysphoria associated with nicotine withdrawal in rats.
Bruijnzeel AW; Ford J; Rogers JA; Scheick S; Ji Y; Bishnoi M; Alexander JC
Pharmacol Biochem Behav; 2012 Mar; 101(1):62-8. PubMed ID: 22182462
[TBL] [Abstract][Full Text] [Related]
28. The effect of ((-)-2-oxa-4-aminobicyclo[3.1.0]hexane-2,6-dicarboxylic acid (LY379268), an mGlu2/3 receptor agonist, on EEG power spectra and coherence in ketamine model of psychosis.
Fujáková M; Páleníček T; Brunovský M; Gorman I; Tylš F; Kubešová A; Řípová D; Krajča V; Horáček J
Pharmacol Biochem Behav; 2014 Jul; 122():212-21. PubMed ID: 24631484
[TBL] [Abstract][Full Text] [Related]
29. Evidence for the role of metabotropic glutamate (mGlu)2 not mGlu3 receptors in the preclinical antipsychotic pharmacology of the mGlu2/3 receptor agonist (-)-(1R,4S,5S,6S)-4-amino-2-sulfonylbicyclo[3.1.0]hexane-4,6-dicarboxylic acid (LY404039).
Fell MJ; Svensson KA; Johnson BG; Schoepp DD
J Pharmacol Exp Ther; 2008 Jul; 326(1):209-17. PubMed ID: 18424625
[TBL] [Abstract][Full Text] [Related]
30. Corticotropin-releasing factor-1 receptor activation mediates nicotine withdrawal-induced deficit in brain reward function and stress-induced relapse.
Bruijnzeel AW; Prado M; Isaac S
Biol Psychiatry; 2009 Jul; 66(2):110-7. PubMed ID: 19217073
[TBL] [Abstract][Full Text] [Related]
31. The mGlu2/3 receptor agonist LY379268 injected into cortex or thalamus decreases neuronal injury in retrosplenial cortex produced by NMDA receptor antagonist MK-801: possible implications for psychosis.
Carter K; Dickerson J; Schoepp DD; Reilly M; Herring N; Williams J; Sallee FR; Sharp JW; Sharp FR
Neuropharmacology; 2004 Dec; 47(8):1135-45. PubMed ID: 15567423
[TBL] [Abstract][Full Text] [Related]
32. Impulsive behaviour in rats induced by intracortical DOI infusions is antagonized by co-administration of an mGlu2/3 receptor agonist.
Wischhof L; Hollensteiner KJ; Koch M
Behav Pharmacol; 2011 Dec; 22(8):805-13. PubMed ID: 22015807
[TBL] [Abstract][Full Text] [Related]
33. Chronic treatment with the vasopressin 1b receptor antagonist SSR149415 prevents the dysphoria associated with nicotine withdrawal in rats.
Qi X; Guzhva L; Ji Y; Bruijnzeel AW
Behav Brain Res; 2015 Oct; 292():259-65. PubMed ID: 26112757
[TBL] [Abstract][Full Text] [Related]
34. Sex differences in the reward deficit and somatic signs associated with precipitated nicotine withdrawal in rats.
Tan S; Xue S; Behnood-Rod A; Chellian R; Wilson R; Knight P; Panunzio S; Lyons H; Febo M; Bruijnzeel AW
Neuropharmacology; 2019 Dec; 160():107756. PubMed ID: 31487496
[TBL] [Abstract][Full Text] [Related]
35. Effects of prazosin, clonidine, and propranolol on the elevations in brain reward thresholds and somatic signs associated with nicotine withdrawal in rats.
Bruijnzeel AW; Bishnoi M; van Tuijl IA; Keijzers KF; Yavarovich KR; Pasek TM; Ford J; Alexander JC; Yamada H
Psychopharmacology (Berl); 2010 Dec; 212(4):485-99. PubMed ID: 20697697
[TBL] [Abstract][Full Text] [Related]
36. Pharmacological and pharmacokinetic properties of a structurally novel, potent, and selective metabotropic glutamate 2/3 receptor agonist: in vitro characterization of agonist (-)-(1R,4S,5S,6S)-4-amino-2-sulfonylbicyclo[3.1.0]-hexane-4,6-dicarboxylic acid (LY404039).
Rorick-Kehn LM; Johnson BG; Burkey JL; Wright RA; Calligaro DO; Marek GJ; Nisenbaum ES; Catlow JT; Kingston AE; Giera DD; Herin MF; Monn JA; McKinzie DL; Schoepp DD
J Pharmacol Exp Ther; 2007 Apr; 321(1):308-17. PubMed ID: 17204749
[TBL] [Abstract][Full Text] [Related]
37. Nicotine potentiation of brain stimulation reward reversed by DH beta E and SCH 23390, but not by eticlopride, LY 314582 or MPEP in rats.
Harrison AA; Gasparini F; Markou A
Psychopharmacology (Berl); 2002 Feb; 160(1):56-66. PubMed ID: 11862374
[TBL] [Abstract][Full Text] [Related]
38. The nicotinic antagonist methyllycaconitine has differential effects on nicotine self-administration and nicotine withdrawal in the rat.
Markou A; Paterson NE
Nicotine Tob Res; 2001 Nov; 3(4):361-73. PubMed ID: 11694204
[TBL] [Abstract][Full Text] [Related]
39. The preclinical properties of a novel group II metabotropic glutamate receptor agonist LY379268.
Imre G
CNS Drug Rev; 2007; 13(4):444-64. PubMed ID: 18078428
[TBL] [Abstract][Full Text] [Related]
40. Chronic bupropion differentially alters the reinforcing, reward-enhancing and conditioned motivational properties of nicotine in rats.
Paterson NE; Balfour DJ; Markou A
Nicotine Tob Res; 2008 Jun; 10(6):995-1008. PubMed ID: 18584463
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
